Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3821 and Fruquintinib in Advanced Colorectal Cancer
NCT07515820Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Jul 2027
01
Overview
Phase 2, open-label, single-arm trial of SHR-3821 in colorectal cancer (CRC). Primary endpoints: Incidence of treatment related adverse event at 90 days and Objective response rate at 6 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
SHR-3821
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07515820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515820.